Xalkori (crizotinib) - Important Safety Information from Pfizer Healthcare Ireland as approved by the HPRA (03.11.22)

Notice type: 3rd Party Publications

Date: 09/11/2022




Problem Or Issue:

Important Safety Information from Pfizer Healthcare Ireland regarding Xalkori (crizotinib): vision disorders, including risk of severe visual loss, need for monitoring in paediatric patients

Important Safety Information – Xalkori (crizotinib)





« Back